UK-based clinical stage biopharmaceutical company Verona Pharma plc is on a mission to develop and commercialize therapies for respiratory diseases that have yet to see adequate medical attention. The company's primary product candidate, ensifentrine, is a dual inhibitor of phosphodiesterase (PDE) 3 and PDE4 enzymes that can simultaneously act as both a bronchodilator and an anti-inflammatory drug. With Phase 3 clinical trials underway, ensifentrine is being studied for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis in three formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc, established in 2005, is headquartered in London.